

**STUDIES OF THE THERAPEUTIC EFFICACY OF  
SELECTED MICRONUTRIENTS IN MALARIA**

**A THESIS SUBMITTED TO THE UNIVERSITY OF LAGOS,  
LAGOS, NIGERIA IN FUFILMENT OF THE REQUIREMENTS  
FOR THE AWARD OF DOCTOR OF PHILOSOPHY (Ph.D)  
DEGREE IN PHARMACOLOGY**

**BY**

**IRIBHOGBE, OSEDE IGNIS**

**069096003**

**FEBRUARY, 2014**

## **DECLARATION**

I hereby declare that this thesis titled “Studies of the Therapeutic Efficacy of Selected Micronutrients in Malaria” submitted to the School of Postgraduate Studies, University of Lagos, Lagos, Nigeria for the award of Doctor of Philosophy in Pharmacology was original research carried out by Iribhogbe, Osede Ignis in the Department of Pharmacology, Therapeutics and Toxicology, College of Medicine University of Lagos, under the supervision of Dr (Mrs) E.O. Agbaje and Dr A.I. Oreagba.

The work has not been submitted previously, in whole or in part, to qualify for any other academic award.

---

**Iribhogbe, Osede Ignis (Student)**

---

**DR (Mrs) E.O. Agbaje (Supervisor)**

Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Idi-Araba P.M.B. 12003 Lagos, Nigeria.

---

**DR A.I. Oreagba (Supervisor)**

Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Idi-Araba P.M.B. 12003 Lagos, Nigeria.



## **DEDICATION**

I dedicate this work to God Almighty, whose benevolence provided the grace, and strength with which this work was executed, to my wife and daughters from whose support I draw my strength as well as those who have been supportive to my educational pursuit.

## ACKNOWLEDGEMENTS

From the depth of the well of joy in my heart I thank the Lord God Almighty for keeping me under the shadow of his everlasting arm. He has been to me a relentless source of inspiration and strength, may his name be praised forever more.

My sincere gratitude goes to my Supervisor Dr (Mrs.) E.O Agbaje, a mother and a rare gem with an excellent spirit of commitment who painstakingly supervised this work and ensured a thorough work was done. I also appreciate my co-supervisor Dr A.I Oreagba, who is a pacesetter and an encouragement to the younger generation of 'academics.' My unalloyed appreciation also goes to Dr O.O Aina who assisted me in securing a laboratory space at the Nigerian Institute of Medical Research, Yaba, as well as providing technical assistance. I also appreciate all my colleagues and friends in the Department of Pharmacology, University of Lagos, for giving me the needed encouragement throughout the period of this study.

I profoundly appreciate my Mother, Mrs. S.E Iribhogbe and all my siblings for their undying devotion and prayers. My profound gratitude also goes to my wife, Mrs. J.O Iribhogbe, for her undying love, devotion and understanding, despite the intense physical strain that resulted from this study and to my lovely kids Recovery and Michelle Iribhogbe.

My appreciation also goes to Prof. (Mrs) O.O Adeyemi, Dr S.O Olayemi, Dr O Awodele, Mr G.O Afolayan, Dr I.O Ishola, Dr A.J Akindele, Mr O.A Salako and Miss F.R Aigbe. I also appreciate Mr D.A Ota and Mr C.M Chijioke for their technical support. My profound appreciation goes to Mr Uwaifoh Akpamu and Dr A.O Nwaopara for their contributions, constructive criticism and support. I immensely appreciate Dr Emordi J. E and Dr. Akahomen J.E, for providing support as physicians during the clinical trials. My profound gratitude also goes to Prof. O.P.G

Nmorsi for supervising the clinical trials. My thanks go to all the nurses and staff of Faithdome Medical Centre. I also appreciate Dr Emilike, Mr Olafeide and Mr Ejiro, the Laboratory Scientist who provided immense technical support during this work. I appreciate Mr Aigbe, nurses of Central Primary Health Centre and the PHC co-coordinator of Esan West Local Government for their unalloyed support and contributions.

Finally, I thank all Parents/Guardian who voluntarily consented to the participation of their children/wards and for giving me the opportunity to contribute to the wealth of human knowledge.

## TABLE OF CONTENTS

TITLE PAGE.....	i
DECLARATION.....	ii
CERTIFICATION.....	iii
DEDICATION.....	iv
ACKNOWLEDGEMENTS.....	v
TABLE OF CONTENTS.....	vii
LIST OF TABLES.....	ix
LIST OF FIGURES.....	xi
LIST OF PLATES.....	xiii
ABSTRACT.....	xiv
<b>CHAPTER ONE</b>	
<b>1.0 INTRODUCTION.....</b>	<b>1</b>
<b>1.1 Background of Study.....</b>	<b>1</b>
<b>1.2 Statement of Problem.....</b>	<b>3</b>
<b>1.3 Justification for the Selection of Micronutrients.....</b>	<b>4</b>
<b>1.4 Aims and Objectives.....</b>	<b>4</b>
<b>1.5 Significance of Study.....</b>	<b>5</b>
<b>1.6 Limitation of Scope of Study.....</b>	<b>6</b>
<b>1.7 List of Abbreviations.....</b>	<b>6</b>
<b>1.8 Definition of Operational Terms.....</b>	<b>7</b>
<b>CHAPTER TWO</b>	
<b>2.0 LITERATURE REVIEW.....</b>	<b>10</b>
<b>2.1 Epidemiology.....</b>	<b>10</b>
<b>2.2 Plasmodium Species Infecting Humans.....</b>	<b>14</b>
<b>2.3 Transmission/Clinical Manifestations.....</b>	<b>28</b>
<b>2.4 Pathogenesis of Severe Malaria.....</b>	<b>34</b>

<b>2.5 Immunity.....</b>	<b>39</b>
<b>2.6 Malaria in Nigeria.....</b>	<b>42</b>
<b>2.7 Prevention and Control.....</b>	<b>43</b>
<b>2.8 Available Agents.....</b>	<b>46</b>
<b>2.9 Cellular and Molecular Biology of Plasmodium.....</b>	<b>67</b>
<b>2.10 Antimalarial Drug Discovery: Old and New Approaches.....</b>	<b>94</b>
<b>2.11 Plasmodium <i>berghei berghei</i>.....</b>	<b>132</b>
<b>2.14 Nutritional Modulation of Malaria Morbidity and Mortality...</b>	<b>134</b>
<b>CHAPTER THREE</b>	
<b>3.0 MATERIALS AND METHODS.....</b>	<b>157</b>
<b>3.1 <i>In vivo</i> Studies.....</b>	<b>157</b>
<b>3.2 Clinical Studies.....</b>	<b>167</b>
<b>CHAPTER FOUR</b>	
<b>4.0 RESULTS.....</b>	<b>178</b>
<b>4.1 <i>In Vivo</i> Studies.....</b>	<b>178</b>
<b>4.2 Clinical Studies.....</b>	<b>217</b>
<b>CHAPTER FIVE</b>	
<b>5.0 DISCUSSION.....</b>	<b>243</b>
<b>5.1 SUMMARY OF FINDINGS.....</b>	<b>264</b>
<b>5.2 CONCLUSION.....</b>	<b>267</b>
<b>5.3 RECOMMENDATIONS.....</b>	<b>268</b>
<b>5.4 CONTRIBUTIONS TO KNOWLEDGE.....</b>	<b>269</b>
<b>REFERENCES.....</b>	<b>270</b>
<b>APPENDICES.....</b>	<b>354</b>

## LIST OF TABLES

<b>Table 1:</b> Drug Administration in the Study Population.....	172
<b>Table 2:</b> Mean Parasitemic Levels of Established <i>P. berghei</i> Infection after 4 Days of Treatment (Curative Test). n = 5 mice per group.....	184
<b>Table 3:</b> Mean Parasitemic Levels of Established <i>P. berghei</i> Infection after 4 Days of Treatment (Curative Synergistic Test). n= 5 mice per group.....	185
<b>Table 4:</b> Chemoprophylactic Effect of Test Agents against <i>P. berghei</i> Infection (n=5 mice per group).....	187
<b>Table 5:</b> Mean Parasitemic Levels of Established <i>P. berghei</i> ( <u>chloroquine resistant ANKA strain</u> ) Infection after 4 Days of Treatment in Curative Synergistic Test. n = 5 mice per group.....	192
<b>Table 6:</b> % Chemosuppression in <i>P. berghei</i> Parasitized mice after 4 days of Treatment.....	198
<b>Table 7:</b> % Hemolysis in Different Groups after 4 Days Curative Test in <i>P. berghei</i> Parasitized Mice.....	199
<b>Table 8:</b> Mean Corpuscular Fragility Index and % Membrane Distability after 4 Day Curative Test in <i>P. berghei</i> Parasitized Mice (n=5 mice each).....	210
<b>Table 9:</b> Lipid Peroxidation and Antioxidant Markers in <i>P. berghei</i> Parasitized Mice after 4 day Curative Treatment (n=5 mice per group).....	212
<b>Table 10:</b> WBC and Platelet Count in <i>P. berghei</i> Parasitized Mice after 4 days of Treatment (n= 5 mice per group).....	215
<b>Table 11:</b> Hematological Profile in <i>P. berghei</i> Parasitized Mice after 4 day Curative Test.....	216
<b>Table 12:</b> Base Line Characteristic of the Study Population (Mean $\pm$ SEM).....	218

<b>Table 13:</b> Socio-Demographic Characteristic of Participants’ Parents/Guardian...	219
<b>Table 14:</b> Base Line Hematological Profile of Participants (Mean ± SEM).....	222
<b>Table 15:</b> Comparative Profile of Total WBC (/mm <sup>3</sup> ) Count on Day 0 of Treatment and Day 28 of Follow Up.....	223
<b>Table 16:</b> Comparative Profile of WBC Differential Count on Day 0 of Treatment and Day 28 of Follow Up.....	224
<b>Table 17:</b> Mean Level of Parasitemia (μL) in Different Groups from Day 0 to Day 2 (D0-D2) of Treatment.....	225
<b>Table 18:</b> Mean Temperature Level (Mean ± SEM) in Different Groups from Day 0 to Day 2 (D0-D2) of Treatment.....	227
<b>Table 19:</b> Correlational Relationship between Parasite Density, Packed Cell Volume, Hemoglobin Concentration and White Blood Cell Count on Day 0.....	231
<b>Table 20:</b> Mean Parasite and Fever Clearance Time (Mean ± SEM) in Different Treatment Groups.....	233
<b>Table 21:</b> Cure Rates (%) in Different Groups Using the “Intention to Treat Population Analysis”.....	235
<b>Table 22:</b> Side Effect Profile of Participants.....	237
<b>Table 23:</b> Comparative Profile of Serum Antioxidant Micronutrients in Children with Uncomplicated Malaria on Day 0 and Day 28 of Treatment.....	239
<b>Table 24:</b> Correlational Relationship between Parasite Density, Serum Retinol, Tocopherol, Ascorbic acid, Zinc and Selenium on Day 0.....	242

## LIST OF FIGURES

<b>Figure 1:</b> Parasitemic profile in negative control group 15 days post-passaging (4 Day Suppressive Test).....	179
<b>Figure 2:</b> % suppression of different test agents in 4-day suppressive test.....	180
<b>Figure 3:</b> % Parasitemia of different test agents in 4 day suppressive test.....	182
<b>Figure 4:</b> Parasitemic Profile of <i>P. berghei</i> 13 days Post-treatment in Curative Test.....	188
<b>Figure 5:</b> Parasitemic Profile of <i>P. berghei</i> 17 days Post-treatment in Curative Synergistic Test.....	190
<b>Figure 6:</b> Normal Thin Blood Film Micrograph in Swiss Albino Mice (X 100 magnification).....	193
<b>Figure 7:</b> Thin Blood Film Micrograph Showing Established <i>P. Berghei</i> Infection (72hrs post inoculation) in Passaged Mice.....	194
<b>Figure 8:</b> Thin Blood Film Micrograph Showing Progressive Parasitisation of RBC in Control Group (X 100 magnification).....	195
<b>Figure 9:</b> Thin Blood Film Micrograph Showing Reduced Erythrocyte Infection with <i>P. Berghei</i> in Vitamin A Treated Group.....	196
<b>Figure 10:</b> Thin Blood Film Micrograph Showing Reduced Erythrocyte Infection with <i>P. berghei</i> in Selenium Treated Group (X 100 magnification).....	197
<b>Figure 11:</b> Osmotic Fragility Curve in Control Group.....	200
<b>Figure 12:</b> Osmotic Fragility Curve in Dist. H <sub>2</sub> O Group.....	201
<b>Figure 13:</b> Osmotic Fragility Curve in Tween 80 Group.....	202
<b>Figure 14:</b> Osmotic Fragility Curve in Chloroquine Group .....	203
<b>Figure 15:</b> Osmotic Fragility Curve in Artesunate Group .....	204

<b>Figure 16:</b> Osmotic Fragility Curve in Vitamin A Group.....	205
<b>Figure 17:</b> Osmotic Fragility Curve in Vitamin E Group.....	206
<b>Figure 18:</b> Osmotic Fragility Curve in Selenium Group.....	207
<b>Figure 19:</b> Osmotic Fragility Curve in Zinc Group.....	208
<b>Figure 20:</b> % Membrane Distability after 4 day Curative Test.....	210
<b>Figure 21:</b> Oxidative Stress and Antioxidant Activity after 4 day Curative Treatment in <i>Plasmodium berghei</i> Parasitized Mice.....	213
<b>Figure 22:</b> Frequency of Malaria Related Symptoms in Participants.....	220
<b>Figure 23a:</b> Temperature Profile in the Treated groups from day 0 to day 28.....	228
<b>Figure 23b:</b> Temperature Profile in the Treated groups from day 0 to day 28.....	229
<b>Figure 23c:</b> Temperature Profile in the Treated groups from day 0 to day 28.....	230
<b>Figure 24:</b> Parasite Clearance rate in Study Participant.....	236
<b>Figure 25:</b> Serum Level of some Antioxidant Micronutrients in Children on Day 0 of Treatment.....	240
<b>Figure 26:</b> Serum Level of some Antioxidant Micronutrients in Children on Day 28 Post-treatment.....	241

## LIST OF PLATES

<b>Plate 1:</b> Different Stages of Plasmodium Species.....	17
<b>Plate 2:</b> Life Cycle of <i>Plasmodium</i> .....	22
<b>Plate 3:</b> A typical temperature pattern (fever) in relation to blood-stage schizogony for the human malaria parasites. The fever paroxysm corresponds to the period of infected erythrocyte rupture and merozoite invasion.....	31
<b>Plate 4:</b> A thin-film Giemsa stained micrograph of ring-forms, and gametocytes of <i>Plasmodium falciparum</i> .....	33
<b>Plate 5:</b> Parasite Invasion of Host cell.....	69
<b>Plate 6:</b> Stages Involved in Host Cell Invasion.....	71
<b>Plate 7:</b> Kinetics of secretion in Toxoplasma.....	75
<b>Plate 8:</b> Transmembrane Junction formation.....	78
<b>Plate 9:</b> Micrograph of Microneme and Dense Granule.....	79
<b>Plate 10:</b> Current model of the motor protein complex driving gliding motility.....	83
<b>Plate 11:</b> Structural Alteration of Host Erythrocyte.....	87
<b>Plate 12:</b> Structure of PfEMP1.....	88
<b>Plate 13:</b> Endothelial Cell Cytoadherence.....	93

## ABSTRACT

The role of selected antioxidant micronutrients in the course and therapy of malaria was elucidated *in vivo* and in a randomized controlled clinical trial. In this study, the rodent malaria model using *Plasmodium berghei* (NK-65 chloroquine sensitive and chloroquine resistant ANKA strain) was used. In the first stage of the experiment, a 4 day suppressive test was conducted using 40 mice of either sex weighing  $20.05 \pm 0.02$  g which were inoculated intraperitoneally with  $1 \times 10^7$  million *Plasmodium berghei* infected erythrocyte and were administered with 0.2 ml of distilled water, 0.2 ml of vehicle; Tween 80 (control and vehicle group), chloroquine 25 mg/kg (standard drug group), vitamin A 60 mg/kg, vitamin E 100 mg/kg, selenium 1 mg/kg, zinc 100 mg/kg and vitamin C 200 mg/kg ( represent test group D, E, F, G, H respectively which were administered orally) 3 hours post inoculation. Similarly, curative, curative synergistic and prophylactic tests were done. In the randomized controlled clinical trial, 150 participants (6 months-5 years) were recruited for the study from Faith-dome Medical Centre and Central Primary Health Centre Ekpoma, Edo State Nigeria, after obtaining ethical clearance from the ethical review Board of the Edo State Ministry of Health. The participants were randomized into 15 cohorts of 10 patients each. The patients in the active comparator group or control group were administered with oral doses of standard artemisinin based combination therapy, while the interventional cohorts were administered varying combinations of antimalarials (Artesunate or Amodiaquine) and micronutrients (vitamin A, vitamin E, zinc and selenium). Results showed that selenium demonstrated significant ( $P < 0.05$ ) chemosuppressive (82.01%) and schizonticidal activity (76.16%) when compared with control during the 4 day suppressive and 4 day curative test respectively.

Curative synergistic study (using chloroquine resistant ANKA strain) showed that the artesunate + selenium combination group ( $2.40 \pm 0.40$  days), had a more rapid parasite clearance time when compared with the artesunate + chloroquine group ( $2.60 \pm 0.24$  days). This was significant ( $F = 13.83$ ;  $P < 0.05$ ) when compared to control and between groups. Findings from the clinical trial revealed that a more rapid parasite clearance time (PCT) was observed in the Artesunate + vitamin A + zinc treated group ( $26.00 \pm 4.82$  hours) when compared with the active comparator groups (Amodiaquine + Artesunate;  $27.00 \pm 3.00$  hours and Artemether + Lumefantrine;  $29.33 \pm 3.53$  hours). Conclusively, the use of varying bi-combinations of antioxidant micronutrients as well as with standard antimalarials have been shown by this study to be of immense benefit in malaria therapeutics, hence this option should be explored as a low cost effective strategy in the management of acute uncomplicated *falciparum* malaria.